Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
41.49
+1.95 (4.93%)
Dec 20, 2024, 4:00 PM EST - Market closed
Protagonist Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 323.8 | 60 | 26.58 | 27.36 | 28.63 | 0.23 | Upgrade
|
| Revenue Growth (YoY) | - | 125.73% | -2.84% | -4.44% | 12293.07% | -99.25% | Upgrade
|
| Gross Profit | 323.8 | 60 | 26.58 | 27.36 | 28.63 | 0.23 | Upgrade
|
| Selling, General & Admin | 42.56 | 33.49 | 31.74 | 27.2 | 18.64 | 15.75 | Upgrade
|
| Research & Development | 132.12 | 120.16 | 126.22 | 126.01 | 74.51 | 65 | Upgrade
|
| Operating Expenses | 174.68 | 153.65 | 157.95 | 153.2 | 93.14 | 80.75 | Upgrade
|
| Operating Income | 149.11 | -93.65 | -131.37 | -125.85 | -64.52 | -80.52 | Upgrade
|
| Interest Expense | - | - | - | - | -0.6 | -0.17 | Upgrade
|
| Interest & Investment Income | 23.7 | 14.9 | 4.06 | 0.44 | 0.9 | 2.81 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.26 | -0.2 | -0.08 | -0.15 | -0.05 | -0 | Upgrade
|
| EBT Excluding Unusual Items | 173.08 | -78.96 | -127.39 | -125.55 | -64.26 | -77.88 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.59 | - | Upgrade
|
| Pretax Income | 173.08 | -78.96 | -127.39 | -125.55 | -64.85 | -77.88 | Upgrade
|
| Income Tax Expense | 2.23 | - | - | - | 1.31 | -0.69 | Upgrade
|
| Net Income | 170.85 | -78.96 | -127.39 | -125.55 | -66.15 | -77.19 | Upgrade
|
| Net Income to Common | 170.85 | -78.96 | -127.39 | -125.55 | -66.15 | -77.19 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 57 | 49 | 46 | 34 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 57 | 49 | 46 | 34 | 26 | Upgrade
|
| Shares Change (YoY) | 17.78% | 15.74% | 5.87% | 34.67% | 32.84% | 15.78% | Upgrade
|
| EPS (Basic) | 2.80 | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 | Upgrade
|
| EPS (Diluted) | 2.68 | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 | Upgrade
|
| Free Cash Flow | 229.23 | -70.85 | -108.93 | -108.97 | -72.96 | -42.49 | Upgrade
|
| Free Cash Flow Per Share | 3.61 | -1.25 | -2.22 | -2.35 | -2.12 | -1.64 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 46.05% | -156.09% | -494.24% | -460.01% | -225.36% | -34857.58% | Upgrade
|
| Profit Margin | 52.76% | -131.59% | -479.26% | -458.94% | -231.07% | -33414.29% | Upgrade
|
| Free Cash Flow Margin | 70.79% | -118.08% | -409.81% | -398.31% | -254.84% | -18395.67% | Upgrade
|
| EBITDA | 150.07 | -92.68 | -130.34 | -125.03 | -63.57 | -79.79 | Upgrade
|
| EBITDA Margin | 46.35% | -154.46% | - | - | -222.05% | - | Upgrade
|
| D&A For EBITDA | 0.96 | 0.98 | 1.03 | 0.81 | 0.95 | 0.73 | Upgrade
|
| EBIT | 149.11 | -93.65 | -131.37 | -125.85 | -64.52 | -80.52 | Upgrade
|
| EBIT Margin | 46.05% | -156.09% | - | - | -225.36% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.